NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020.
Publication
, Journal Article
Becker, PS; Griffiths, EA; Alwan, LM; Bachiashvili, K; Brown, A; Cool, R; Curtin, P; Dinner, S; Gojo, I; Hicks, A; Kallam, A; Kidwai, WZ ...
Published in: J Natl Compr Canc Netw
January 2020
Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN. These NCCN Guidelines are intended to guide clinicians in the appropriate use of growth factors for select patients undergoing treatment of nonmyeloid malignancies. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines regarding the incorporation of newly FDA-approved granulocyte-colony stimulating factor biosimilars for the prevention and treatment of FN.
Duke Scholars
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
January 2020
Volume
18
Issue
1
Start / End Page
12 / 22
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Risk Factors
- Practice Guidelines as Topic
- Organizations, Nonprofit
- Oncology & Carcinogenesis
- Oncologists
- Neoplasms
- Medical Oncology
- Humans
Citation
APA
Chicago
ICMJE
MLA
NLM
Becker, P. S., Griffiths, E. A., Alwan, L. M., Bachiashvili, K., Brown, A., Cool, R., … Pluchino, L. A. (2020). NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. J Natl Compr Canc Netw, 18(1), 12–22. https://doi.org/10.6004/jnccn.2020.0002
Becker, Pamela Sue, Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, et al. “NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020.” J Natl Compr Canc Netw 18, no. 1 (January 2020): 12–22. https://doi.org/10.6004/jnccn.2020.0002.
Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, et al. NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. J Natl Compr Canc Netw. 2020 Jan;18(1):12–22.
Becker, Pamela Sue, et al. “NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020.” J Natl Compr Canc Netw, vol. 18, no. 1, Jan. 2020, pp. 12–22. Pubmed, doi:10.6004/jnccn.2020.0002.
Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Dinner S, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Miller R, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Rosovsky R, Roy V, Rugo HS, Shayani S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Burns J, Keller J, Pluchino LA. NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. J Natl Compr Canc Netw. 2020 Jan;18(1):12–22.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
January 2020
Volume
18
Issue
1
Start / End Page
12 / 22
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Risk Factors
- Practice Guidelines as Topic
- Organizations, Nonprofit
- Oncology & Carcinogenesis
- Oncologists
- Neoplasms
- Medical Oncology
- Humans